QSI Pharma AS

QSI Pharma, a Danish start up formed by the Technical University of Denmark and the biotech incubator of Leo Pharma AS, aims to inhibit the formation of deadly biofilms, highly structured and virulent communities of surface colonizing bacteria. QSI aims to discover molecules that interfere with bacterial quorum sensing, a cell-cell signaling process by which bacteria form biofilms when sufficient bacteria have amassed. The company's first target is Pseudomonas aeruginosa, which is responsible for a significant percentage of deaths from many hospital-acquired infections.

Biofilms, highly structured and virulent communities of surface colonizing bacteria, are patient, yet lethal invaders. Through a cell-cell signaling process known as quorum sensing, bacteria that form biofilms wait until sufficient numbers of microorganisms have amassed. Then they attack their host through a coordinated launch of virulence factors including tissue degrading enzymes and other toxic substances. In addition to causing various problems in industrial settings, ranging from corrosion and clogging to food contamination, biofilms cause chronic, stubborn and deadly infections in clinical settings.

[QSI Pharma AS] , a Danish start-up formed by the Technical University of Denmark (DTU) and Leo Incubator, the biotech...

More from Global Vision

UK Bets On Regulatory Innovation As Competitive Advantage In Synthetic Biology

 
• By 

The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By 

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Unpacking The Impact Of Trump’s Tariffs On Drug Pricing And Production

 
• By 

Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.

Barcelona’s S2 Xpeed Accelerates Hardware-Based Medtech Start-Ups From Prototype To Market

 
• By 

S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity.

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By 

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.